BusinessGlobal Blood Therapeutics Prices a $100.0 Million Common Stock Public OfferingBy Nasdaq OMXDec 15, 2017, 2:03 PM UTC
BusinessGlobal Blood Therapeutics Announces Proposed Public Offering of Common StockBy Nasdaq OMXDec 14, 2017, 9:01 PM UTC
BusinessGBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) ProgramBy Nasdaq OMXDec 11, 2017, 12:00 PM UTC
BusinessGBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)By Nasdaq OMXDec 9, 2017, 3:00 PM UTC
BusinessGlobal Blood Therapeutics Announces New Employment Inducement GrantsBy Nasdaq OMXNov 30, 2017, 9:05 PM UTC
BusinessGlobal Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell DiseaseBy Nasdaq OMXNov 13, 2017, 1:00 PM UTC
BusinessGlobal Blood Therapeutics Announces Participation at the Stifel 2017 Healthcare ConferenceBy Nasdaq OMXNov 7, 2017, 9:06 PM UTC
BusinessGlobal Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 2, 2017, 8:05 PM UTC
